Publications by authors named "C Cittanti"
Article Synopsis
- The approval of radioligand therapy (RLT) by EMA in 2017 and FDA in 2018 has led to its broader use in treating neuroendocrine neoplasms (NENs), particularly advanced well-differentiated gastro-entero-pancreatic types.
- However, RLT applications are limited to specific tumor types, leaving some tumors, like those from the sympathetic-adrenal-medullary (SAM) axis, as "RLT-orphans" that cannot currently benefit from this therapy.
- The paper explores theragnostic options for treating pheochromocytomas and paragangliomas, discussing traditional methods with MIBG and potential future applications using radiolabeled somat
A 73-year-old male with left hip prosthesis infection performed a Tc HMPAO-labelled autologous WBC (WBC) scan to evaluate the response to antibiotic therapy. Since the early planar scan, an area of increased activity was visible extending from the left groin region to the ipsilateral flank. At late planar images, the area progressively focused in the left groin, site of a painful inguinal hernia.
View Article and Find Full Text PDFArticle Synopsis
- The study explores the use of FAPI PET/CT imaging in various urological cancers, particularly prostate, urothelial, and renal cell carcinomas.
- Preliminary findings suggest FAPI PET can detect primary prostate cancer even with low prostate-specific membrane antigen expression, although it is less effective than prostate-specific membrane antigen PET/CT for spotting recurrence.
- FAPI PET/CT shows improved detection rates for small lymph node metastases in urothelial carcinoma compared to traditional imaging, highlighting its potential, especially for bladder cancer, but more research is needed to fully understand its clinical applications.
Unlabelled: Oligometastatic patients at [F]F-Fluorocholine (F-choline) PET/CT may be treated with metastasis-directed therapy (MDT). The aim of this study was to combine radiomic parameters extracted from F-choline PET/CT and clinical data to build machine learning (ML) models able to predict MDT efficacy.
Methods: Oligorecurrent patients (≤5 lesions) at F-choline PET/CT and treated with MDT were collected.
Background: prostate-specific membrane antigen (PSMA) ligand PET has been recently incorporated into international guidelines for several different indications in prostate cancer (PCa) patients. However, there are still some open questions regarding the role of PSMA ligand PET in castration-resistant prostate cancer (CRPC). The aim of this work is to assess the clinical value of PSMA ligand PET/CT in patients with CRPC.
View Article and Find Full Text PDF